This insider cluster is routine and non-informative. The sales are small, follow option exercises, and are likely liquidity-driven. No bearish read-through. Monitor for any material news (pipeline updates, partnership announcements) that could explain the option exercises, but the cluster itself does not warrant action.
NRIX drugs
NRIX drug pipeline →- ▲ bexobrutideg 5/10 Phase 1a/b (pivotal Phase 2 underway; Phase 3 planned summer 2026)
- ● GS-6791 4/10 Phase 1
- ● NX-1607 4/10 Phase 1 (Phase 1a dose escalation complete; Phase 1b expansion planned)
- ● zelebrudomide 3/10 Phase 1
- ● NX-3911 2/10 Preclinical / IND-enabling — Phase 1 trial authorized (EU CTIS) but not yet recruiting
- All NRIX drugs, catalysts & trials →
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jul 31 $23.21entry
- T+1 · 4mo ago +0.04%α −1.38% · $23.22
- T+5 · 3mo ago +10.00%α +6.48% · $25.53
- T+20 · 3mo ago +12.93%α +9.94% · $26.21
- T+60 · 22d ago +10.08%α +7.63% · $25.55
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Three C-suite insiders at Nurix Therapeutics (CFO, CSO, CLO) exercised stock options and immediately sold a combined ~$246K in open-market sales on July 30, 2026. The sales are small relative to the $2.4B market cap (~0.01%) and coincide with option exercises, suggesting tax-covering or liquidity-driven sales rather than a bearish signal. The cluster is not informative per academic literature, insider sales are weak predictors, and the dollar amount is trivial.
Key Financial Metrics
Key Facts
- Three C-suite insiders (CFO, CSO, CLO) sold a combined ~$246K in open-market sales on July 30, 2026.
- All sales followed option exercises at $0 strike, indicating a cashless exercise-to-sell pattern for tax or liquidity purposes.
- Total sales represent ~0.01% of NRIX's $2.4B market cap, well below the 0.1% materiality threshold.
- The cluster is a single-day event with all trades at the same price ($23.38), consistent with a coordinated vesting/blackout-window opening.
Financial Impact
~$246K in insider sales, ~0.01% of market cap
Risk Factors
- Insider sales are often liquidity-driven and not predictive; this cluster is too small to signal fundamental deterioration.
- No risk of material dilution from option exercises, shares were immediately sold in the open market.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-NRIX-1785448870685 |
Track record
33 reports on NRIX
4 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +53.71% at T+20 after the Jun 8, 2026 report. 6 of 7 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry price pending
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $15.17 Now $14.73 −2.90% settles Dec 15
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $15.41 Now $14.73 −4.41% settles Dec 15
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $14.84 Now $14.73 −0.74% settles Dec 4
- Nov 4, 202612d ago Insider Cluster Neutral 2/10 Entry $14.84 Now $14.73 −0.74% settles Dec 4
- Nov 4, 202612d ago 144 Neutral 2/10 Entry $14.84 Now $14.73 −0.74% settles Dec 4
- Nov 3, 202613d ago 144 Neutral 2/10 Entry $15.95 Now $14.73 −7.65% settles Dec 3
- Nov 3, 202613d ago 8-K Bearish 5/10 Entry $15.95 Now $14.73 +7.65% settles Dec 3
- Nov 2, 202614d ago Insider Cluster Neutral 2/10 Entry $25.82 Now $14.73 −42.95% settles Dec 2
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $25.82 Now $14.73 −42.95% settles Dec 2
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers